6 курс / Кардиология / Коронарное_стентирование_и_стенты

N. Engl. J. Med. 2015. Vol. 373. P. 2038-2047.

70. Karjalainen P.P., Niemella M., Airaksinen J.K.E, Rivero-Crespo F., Romppa-nen H., Sia J., Lalmand J., de Bruyne B., DeBelder A., Carlier M., Nammas W.W., Ylitalo A., Hess O.M. BACE-ACS study investigators. A prospective randomized comparison of titanium-nitrite-oxyde-coated bioactive stents with everolimus elu-ting stents in acute coronary syndrome: The BASE-ACS trial // Eurointervention.

2012. Vol. 3. P. 306-315.

71. Waksman R., Kirtane A.J., Torguson R. et al. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-eluting Stent Event Registry of Thrombosis) // JACC Cardiovasc. Interv.

2014. Vol. 7. P. 1093-1102.

72.Nkazawa G., Vorpahl M., Finn A.V. et al. One Step forward and two steps back with drug-eluting stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis // JACC Cardiovasc. Imaging. 2009. Vol. 2. P. 625-

73.73. Jabib A., Karmali V., Polavarapu R. et al. Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-a activation and disruption of the p120-vascular endothelial cadherin interaction // Arterioscler. Thromb. Vasc.

Biol. 2013. Vol. 33. P. 2425-2431.

74.Otsuka F., Vorpahl M., Nakano N. et al. Pathology of second-generation everoli-mus-eluting stents versus first-generation sirolimusand pacltaxel-eluting stents in humans // Circulation. 2014. Vol. 129. P. 211-223.

75.Oberhauser J.P., Hossainy S., Rapoza R.J. Design principles and performace of bioresrbable polymeric vascular scaffolds // Eurointervention. 2009. Vol. 5.

P. F15-22.

76.Costa Jr J.D.R., Sousa A., Moreira A, Costa Jr R., Cano M., Maldonado G., Siqueira D., Campos C., Damiani L., Romano E., Egito E., Sousa J.E. A decade of experience with DES in the real world clinical practice: 10 year follow-up of the DESIRE registry (abstract) // EuroPCR. May 2013.

77.Nishio S., Kosuga K., Igaki K., Okada M., Kyo E., Tsuji T., Takeuchi E., Inuzu-ka Y., Takeda S., Hata T., Takeuchi Y., Kawada Y., Harita T., Seki J., Akamtsu S., Hasegawa S., Bruining N., Brugaletta S. de Winter S., Muramatsu T., Onuma Y., Serruys P.W., Ikeguchi S. Long-term (>10 Years) clinical outcomes of first-in- human biodegradable poly-L-lactic acid coronary stents: Igaki-Tamai Stents // Circulation. 2012. Vol. 125. P. 2343-2353.

Медицинские книги

@medknigi

78. Ormiston J.A., Serruys P.W., Regar E., Dudek D., Thuesen L., Webster M.W., Onuma Y., Garcia-Garcia H.M., McGreevy R., Vedhof S. A bioabsorbable everolimus-elutingcoronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial // Lancet. 2008. Vol. 371.

P. 899-907.

79. Onuma Y., Dudek D., Thuesen L., Webster M.W., Nieman K., Garcia-Gar-cia H.M., Ormiston J.A., Serruys P.W. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial // JACC Cardiovasc. Interv. 2013.

Vol. 6. P. 999-1009.

80.Dilleti R., Serruys P.W., Farooq V., Sudhir K., Dorange C., Miquel-Hebert K., Vedhof S., Rapoza R., Onuma Y., Garcia-Garcia H.M., Chevalier B. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design // Am. heart J. 2012. Vol. 164. P. 654-663.

81.Serruys P.W., Chevalier B., Cequier A., Dudek D., Carrie D., Iniguez A., Dominici M., van der SchaafR.J., Haude M., Wansungu L., VedhofS., Peng L., Staehr P., Grundeken M.J., Ishibashi Y., Garcia-Garcia H.M., Onuma Y. Bioresorbable everolimus-eluting scaffolds versus a metallic everolimus-eluting stent for ischem-ic heart disease caused by de-novo native coronary artery lesions (ABSORA II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomized controlled trial // Lancet. 2015. Vol. 385. P. 43-54.

82.Serruys P.W., Chevalier B., Sotomi Y., Cequier A., Carrie D., Piek J.J., Van Bo-ven A.J., Dominici M., Dudek D. McClean D., Helqvist S., Haude M., Reith S., de Sousa Almeida M., Campo G., Iniguez A., sabate M., Windecker S., Onuma Y. Comparison of an everolimus-eluting bioresorbable scaffolds with an everoli- mus-eluting metallic stentfor the treatment of coronary artery sienosis (ABSO-RA II): a 3 year, randomized, controlled, single-blind, multicenter clinical trial //

Lancet. 2016. Vol. 388. P. 2479-2491.

83. Pentousis D., Guerin Y., Funck F. et al. Direct stent implantation without predilatation using the multi-link stent // Am. J. Cardiol. 1998. Vol. 82. P. 14371440.

Медицинские книги

@medknigi

84.Clague J.R., Kurbaan A.S., Kelly P.A. et el. The new ASC Multi-link coronary stent: single center experience in 103 consecutive patients with and without oral anticoagulation // J. Interv. Cardiol. 1997. Vol. 10. P. 183-191.

85.Nakano Y., Nakagawa Y., Yukoi H. et al. Initial and follow-up results of the ACS Multi-link stent; a single center experience // Cathet. Cardiovasc. Diagn. 1998.

Vol. 45. P. 368-374.

86.Beyar R. The BeStent. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 1996. P. 153-161.

87.Suryapranata H., Boland J.L., Pieper M. et al. Clinical and agiographic results with the Bestent. The registry for optimal bestent evaluation trial. Submitted for publication.

88.Geis M.W., Tamor M.A. Diamond and dimond like carbon // Encyclo of Appl. Phys. 1993. Vol. 5. P. 1-24.

89.Barragan P., Herbst F., Kalachev A. The Biodiamond and biodiamond F stent. Handbook of Coronary Stents, Serruys P. (ed), London: Martin Dunitz, 2000.

P. 29-39.

90.Zheng H., Barragan P., Corcos T. et al. Clinical evaluation of biocompitable phos-phorylcholin-coated coronary stent // J. Am. Coll Cardiol. 1999. Vol. 33. P. 34A.

91.Fischel D., Fischell T., Fischel R. The BX Velocity stent. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 51-56.

92.Suryapranata H. The CordisLC Multipurpuse Stent System. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 57-61.

93.Savage M.P., Fischman D.L., Rake R. et al. Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries // J. Am. Coll Cardiol. 1988. Vol. 31.

P. 307-311.

94. Konin R.K., Chan C., Eltchaninoff H. et al. Primary stenting of de novo lesions in small coronary arteries: a prospective, pilot study // Cathet. Cardiovasc. Diagn.

1998. Vol. 45. P. 235-238.

95.Wheeldon Nigel M. The Coroflex Coronary stent system. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 71-79.

96.Becker J.G., Kutryk M., Serruys P.W. The Coronary R-stent. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 81-89.

Медицинские книги

@medknigi

97.Ischinger T. The Genius Coronary stent. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 91-97.

98.Alt E., Beilharz C., Preter D. et al. Biodegradable stent coating with polylactic acid, hirudin and prostacyclin reduces restenosis // J. Am. Coll Cardiol. 1997.

Vol. 23(8). P. 961-973.

99.Tashji A., Kanesaka N., Golik G. The Iris stent. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 107-112.

100.Alt E., Elezi S., Zitsmann E. et al. The new InFlowStent: clinical and angiographic results // J. Am. Coll. Cardiol. 1997. Vol. 416. P. 1036-1091.

101.Reifart N., Rossler C. The Jostent coronary stent range. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 113-120.

102.Garckens U., Muller R., Cattelaens N., Herchenbach M., Grube E. The new coronary stent graft Jostent first clinical experience // J. Am. Coll. Cardiol. 1998.

Vol. 31.

103.Meewis D., Katenkamp M. The LP Stent. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 125-129.

104.Schofer J., Mathey D., Haufe M. The MAC and Omega coronary stents. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 131-

134.

105. Lefebvre J-M. The Med-X Stent. Handbook of Coronary Stents, Serruys P. (ed).

London: Martin Dunitz, 2000. P. 135-140.

106.Haberbosch W. Medex Coronary C1 stent. Handbook of Coronary Stents, Ser-ruys P. (ed). London: Martin Dunitz, 2000. P. 141-145.

107.Silber S. The MSM-BMS Coronary stent. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 147-151.

108.Ischinger T.A., Vries D. The nexus coronary stent. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 153-158.

109.Machraoui A., Grosser K.D., Kasiske H.P. et al. The PURA coronary stent. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 159-169.

110.Royer T. The Seaquence Stent. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 171-176.

Медицинские книги

@medknigi

111.Kaae J.L. Gulden T.D. Structure and mechanical properties of co-deposited py-rolic C-SiC alloys // J. Am. Ceram. Soc. 1971. Vol. 54. P. 605-609.

112.Haubold A.D., Shim H.S., Bokros J.C. Biocompitability implant materials. In: Carbon in Medical devices, 1981. Williams D.F., ed, Boca Raton, USA.

113.Cenni E., Granchi D., Arciola C.R. et al. Adhesive protein expression on endothe-lial cells after contact in vitro with polyethylene terephtalate coated with pyrolitic carbon // Biomaterials. 1995. Vol. 16. P. 1223-1227.

114.Lafont A. The Stent Tech Stent. Handbook of Coronary Stents, Serruys P.

(ed).

London: Martin Dunitz, 2000. P. 187-189.

115.Hanekamp C., Bonnier H. A highly flexible slotted tube stent desighn coated with a-SiC: H: first clinical experience // Prog. in Biomed. Res. 1988. Vol. 2.

116.Oesterle S.N., Hayase O., Schuler G., Migyel C.M. et al. A novel stent delivery catheter: The intella trinity Balloon // Cathet. Cardiovasc. Int. 1999. Vol. 46.

P. 498-502.

117. Yokoi H., Nakagawa Y., Tamura T., Hamasaki N., Kimura T., Nosaka H., Nobuy-oshi M. Preliminary experiences with the Terrumo Coronary Stent // J. Am. Coll.

Cardiol. 1998. Vol. 31. P. 413A.

118.Shum L.X., Wang K., Zhou X.R. et al. Experimental evaluation of new tubular coronary stent (V-Flex) // J. Invas. Cardiol. 1988. Vol. 10. P. 539-544.

119.Meens H.J., Horvers R.A. Genic coronary stent. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 421-424.

120.Gracida M., Romaguera R., Jacobi F. et al. The MGuard coronary stent: safety, efficacy, and clinical utility // Vasc. Health Risk. Manag. 2015. Vol. 11. P. 533-539.

121.Stone G.W.1, Abizaid A., Silber S. et al. Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent

(MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial // J. Am. Coll. Cardiol. 2012 Nov 6. Vol. 60(19). P. 1975-1984

122. Асадов Д.А. Сравнительная оценка методов внутрисосудистого ультразвука и оптической когерентной томографии при визуализации внутрисосудистых структур // Международный журнал интервенционной кардиоангиологии.

№ 36. С. 42-47.

Медицинские книги

@medknigi

123.Serruys P.W., Strauss B.H., Beatt K.J. et al. Angiographic follow-up after placement of the coronary Wallstent in native vessels and bypass grafts // Am. J. Cardiol. 1992. Vol. 69. P. 475-481.

124.Ozaki Y., Keene D., Ruygrok P. et al. Six-month clinical and angiographic outcome of the new less shortening Wallstent in native coronary arteries // Circulation. 1996. Vol. 93. P. 2114-2120.

125.Grenadier E., Shofti R., Beyar M. et al. Self-expandable stent versus balloonexpandable stent: immediate and long-term result in dog // Am. Heart. J. 1994.

Vol. 128. P. 870-878.

126.Goldberg S., Schwartz R.S., Mann T.J. et al. Comparison of a novel selfexpandable Nitinol stent (Radius) with balloon-expandable (Palmaz-Schatz) stent: initial results of randomized trial (SCORES) // Circulation. 1997. Vol. 96. P. 654.

127.Hijazi Z.M., Brahimi A., Pacera J.H. et al. Quantitive angiographic outcome after coronary angioplasty using AngioStent // J. Invas. Cardiol. 1996. Vol. 8. P. 47.

128.Seth A., Salwan R., Chandra P. et al. Bailout bifurcation stenting involving Angio-stent through the struts of AVE Microstent // J. Invas. Cardiol. 1997.

129.Park S.J., Park S.W., Honh M.K. et al. Intracoronary stainless stell Cordis (Cross-Flex) stent implantation: initial results and late outcome // Am. J. Cardiol. 1997.

Vol. 80 (suppl. 7A). P. 27S.

130.De Scheerder I., Chevalier B., Vassanelli C. European Freedom stent registry // J. Am. Coll Cardiol. 1997. Vol. 2(29). P. 1080.

131.Chevalier B., Montserrat P., Huguet R. et al. French Freedom stent registry: short-term results // Eur. Heart J. 1996. Vol. 17. P. 2223.

132.Shterzer S.H., Pomerantsev E.V. AVE GFX, GFX-2, S540 and s670 stents. Handbook of Coronary Stents, Serruys P. (ed). London: Martin Dunitz, 2000. P. 262-278.

133.Vad der Giessen W.J., Gollier G., Hoorntje J.C. et al. The ESSEX Study: first clinical experience with the self-expanding nitinol Radius stent (abstract) // Eur. Heart J. 1997. Vol. 18 (suppl.). P. 1-654.

134.Garg S., Franzone A., Serruys P.W., Windecker S. Coronary artery stents in Percutaneous Interventional Cardiovascular Medicine: The PCR-EAPCI Textbook. Digital edition. Editors: Eeckhout E., Serruys P.W., Wijns W., Vahanian A., Van Sambeek, De Palma R. 2015.

135.Palmerini T., Kirtane A.J., Stone G.W. Bare metal and drug-eluting coronary stents in Textbook of Interventional Cardiology. Topol EJ, Teirstein PS. Elsevier,

Медицинские книги

@medknigi

2016.

136. Franzone A., Zaugg S., Piccolo R. A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the

treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study. PLoS One. 2017 Aug 10. Vol. 12(8). P. e0182632. doi: 10.1371/ journal.pone.0182632. eCollection 2017.

137.Cohen D.J., Osnabrugge R.L., Magnuson E.A. et al. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial // Circulation. 2014. Vol. 30, N130(14). P. 11461157.

138.Granada J.F., Huibregtse B.A., Dawkins K.D. New stent design for use in small coronary arteries during percutaneous coronary intervention // Med. Devices

(Auckl). 2010. Vol. 3. P. 57-66.

139.Son J., Kim U., Park J. et al. Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents // Korean. J. Intern. Med. 2013. Vol. 28(1). P. 72-80.

140.Sim D.S., Jeong M.H., Hong Y.J. Safety and Efficacy of the Endeavor

Resolute® Stent in Patients with Multivessel Disease: The HEART (HonamEndeAvorReso-luTe) Prospective, Multicenter Trial // Chonnam. Med. J. 2018. Vol. 54(1). P. 55-62.

141.Bridges J., Cutlip D. Advances in drug eluting stents - focus onThe Endeavor- zo-tarolimus stent // Med. Devices (Auckl). 2009. Vol. 2. P. 1-8.

142.Bennett J., Dubois C. A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease // Biologics. 2013. Vol. 7. P. 149-159.

143.Allocco D., Joshi A., Dawkins K. Everolimus-eluting stents: update on current clinical studies // Med. Devices (Auckl). 2011. Vol. 4. P. 91-98.

144.Schmidt W., Lanzer P., Behrens P. et al. Direct comparison of coronary bare metal vs. drug-eluting stents: same platform, different mechanics? // Eur. J. Med. Res. 2018. [Электронный ресурс] doi: 10.1186/s40001-017-0300-y.

145.Kamberi M., Pinson D., Pacetti S. et al. Evaluation of chemical stability of polymers of XIENCE everolimus-eluting coronary stents in vivo by pyrolysis-gas chro-matography/mass spectrometry // J. Biomed. Mater. Res. B. Appl. Biomater. 2017. [Электронный ресурс] doi: 10.1002/jbm.b.33979.

Медицинские книги

@medknigi

146.Basalus M.W.Z., Tandjung Л., Van Houwelingen K.G. TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: study design, rationale and objectives // Neth. Heart J. 2010. Vol. 18(7-8). P. 360-364.

147.Wilson G.J., Marks A., Berg K.J. et al. The SYNERGY biodegradable polymer everolimus eluting coronary stent: Porcine vascular compatibility and polymer

safety study // Catheter Cardiovasc. Interv. 2015. Vol. 15. N86(6). P. 247-257.

148.Ananthakrishna R., Kristanto W., Liu L. Incidence and predictors of target lesion failure in a multiethnic Asian population receiving the SYNERGY coronary stent: A prospective all-comers registry // Catheter Cardiovasc. Interv. 2018. [Электронный ресурс]doi: 10.1002/ccd.27577.

149.Kereiakes D.J., Meredith I.T., Windecker S. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II

Randomized Trial // Circ. Cardiovasc. Interv. 2015. [Электронный ресурс] doi: 0.1161/CIRCINTERVENTIONS.114.002372.

150.Yang J.X., Yeh R.W. Safety and effectiveness of zotarolimus-eluting stents for percutaneous coronary intervention: a systematic review // Future Cardiol. 2018. [Электронный ресурс]doi: 10.2217/fca-2017-0091.

151.Piccolo R., Stefanini G.G., Franzone A. et al. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a metaanalysis // Circ. Cardiovasc. Interv. 015.[Электронныйресурс] doi: 10.1161/CIRCINTER-

VENTIONS.114.002223.

152.Rawlins J., Din J., Talwar S. et al. AXXESS? Stent: Delivery Indications and Outcomes // Interv. Cardiol. 2015. Vol. 10(2). P. 85-89.

153.Birgelen C., Asano T., Amoroso G.et al. First-in-man randomized comparison of BuMA Supreme biodegradable polymer sirolimus-eluting versus durable polymer zotarolimus-eluting coronary stents: The PIONEER trial // EuroIntervention. 2017. [Электронный ресурс].

154.Woudstra P., de Winter R.J., Beijk M.A. Next-generation DES: the COMBO dual therapy stent with Genous endothelial progenitor capturing technology and an abluminalsirolimus matrix // Expert. Rev. Med. Devices. 2014. Vol. 11(2).

P. 121-135.

155.Reifart N., Hauptmann K., Rabeet A. et al. Pre-Clinical And Clinical Study Results For The Coracto? Rapamycin-Eluting Stent - A New-Generation DrugEluting Stent // ICR. 2010. Vol. 5(1). P. 39-42.

Медицинские книги

@medknigi

156. Iqbal J., Verheye S., Abizaid A. et al. DESynenovolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial // Euro-

Intervention. 2016. Vol. 10, 12(11). P. 1336-1342.

157. Margolis J.R. The Excel Stent: A Good DES, But Can We Really Stop Clopidogrel After 6 Months? Volume 2, Issue 4, April 2009 [электронныйресурс] DOI:

10.1016/j.jcin.2009.01.005.

158. Shuvalova Y.A., Shirokov R.O., Kaminnaya V.I. et al. Two-year follow-up of percutaneous coronary intervention using EucaTax or Cypher // Cardiovasc. Revasc.

Med. 2013. Vol. 14(5). P. 284-288.

159.Gao Z., Zhang R., Xu B. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: two-year results from a prospective patient-level pooled analysis of TARGET trials // Catheter Cardiovasc. Interv. 2015. Vol. 85. N 1. P. 734-

160.Oliveira M.D., Ribeiro E.E., Campos C.M. et al. // Cardiovasc. Diagn. Ther. 2015. Vol. 5(4). P. 264-270.

161.Grube E., Schofer J., Hauptmann K.E. et al. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent // JACC Cardiovasc. Interv. 2010. Vol. 3(4). P. 431-438.

162.McCLAIN J.B., Carlyle W.C., Donohoe D.J. et al. Technical overview on the MiStent coronary stent // Minerva Cardioangiol. 2016. Vol. 64(5). P. 560-571.

163.Jain R.K., Chakravarthi P., Shetty R. et al. One-year outcomes of a BioMime? Sirolimus-Eluting Coronary Stent System with a biodegradable polymer in allcomers coronary artery disease patients: The meriT-3 study // Indian Heart J. 2016. Vol. 68(5). P. 599-603.

164.Dani S., Costa R.A., Joshi H. et al. First-in-human evaluation of the novel Bio- Mimesirolimus-eluting coronary stent with bioabsorbable polymer for the treatment of single de novo lesions located in native coronary vessels - results from the meriT-1 trial // EuroIntervention. 2013. Vol. 22. N9(4). P. 493-500.

165.Belardi J.A. Nevo stent: a successful stent makeover // Catheter Cardiovasc. Interv. 2011. Vol. 77(1). P. 52-53.

166.GakuNakazawa, Sho Torii, Takeshi Ijichi. Comparison of Vascular Responses Following New-Generation Biodegradable and Durable Polymer-Based Drug-

Медицинские книги

@medknigi

Eluting Stent Implantation in an Atherosclerotic Rabbit Iliac Artery Model // J. Am. Heart. Assoc. 2016. [Электронный ресурс]doi: 10.1161/JAHA.116.003803.

167.Wilkes Evans L., Doran P., Marco P. XTENT(R) Custom NX drug eluting stent systems // EuroIntervention. 2007. Vol. 3(1). P. 158-161.

168.Stella P.R., Mueller R., Pavlakis G. One year results of a new in situ lengthadjustable stent platform with a biodegradable biolimus A9 eluting p olymer: results of the CUSTOM-II trial // EuroIntervention. 2008. Vol. 4(2). P. 200-207.

169.Lukovic D., Nyolczas N., Hemetsberger R. et al. Human recombinant activated protein C-coated stent for the prevention of restenosis in porcine coronary arteries // J. Mater. Sci. Mater. Med. 2015. Vol. 26(10). P. 241.

170.Kufner S., Byrne R.A., Valeskini M. et al. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial // EuroIntervention. 2016. Vol. 11(12). P. 1372-1379.

171.Iglesias J.F., Roffi M., Degrauwe S. et al. Orsiro cobalt-chromium sirolimus- elut-ing stent: present and future perspectives // Expert. Rev. Med. Devices. 2017. Vol. 14(10). P. 773-788.

172.Lipinski M.J., Forrestal B.J., Iantorno M. et al. A comparison of the ultrathin Orsiro Hybrid sirolimus-eluting stent with contemporary drug-eluting stents: A meta-analysis of randomized controlled trials // Cardiovasc. Revasc. Med. 2018. Vol. 19(1 Pt A). P. 5-11.

173.Kume T., Waseda K., Koo B.K. et al. Intravascular ultrasound analysis of small vessel lesions treated with the Sparrow coronary stent system: results of the CARE II trial // Catheter Cardiovasc. Interv. 2014. Vol. 1. N83(1). P. 19-24.

174.Lemos P.A., Bienert I. The Supralimussirolimus-eluting stent // Expert. Rev. Med. Devices. 2013. Vol. 10(3). P. 295-300.

175.Dani S., Kukreja N., Parikh P. et al. Biodegradable-polymer-based, sirolimus- elu-ting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study // EuroIntervention. 2008. Vol. 4(1). P.

59-63.

176.Verheye S. Evaluation of the Svelte Medical systems SLENDER IDS Siroli- mus-eluting coronary stent-on-a-wire integrated delivery system for the treat-

ment of coronary artery disease // Expert. Rev. Med. Devices. 2017. Vol. 14(9). P. 669-683.

177. Longo G., La Manna A., Capodanno D. et al. The Ultimaster® coronary stent system: state of the art // Minerva Cardioangiol. 2015. Vol. 63(3). P. 193-203.

Медицинские книги

@medknigi